Bank Of New York Mellon Corp Janux Therapeutics, Inc. Transaction History

Bank Of New York Mellon Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$11.25 - $22.21 $597,273 - $1.18 Million	53,091 New	53,091 $642 Million
Q4 2022 Feb 14, 2023	BUY	$11.1 - $18.26 $593,905 - $977,001	53,505 New	53,505 $704,000
Q3 2022 Nov 14, 2022	BUY	$10.82 - $16.84 $83,389 - $129,785	7,707 Added 18.18%	50,093 $679,000
Q2 2022 Aug 15, 2022	SELL	$9.52 - $15.65 $34,414 - $56,574	-3,615 Reduced 7.86%	42,386 $517,000
Q1 2022 May 11, 2022	BUY	$13.24 - $20.24 $125,303 - $191,551	9,464 Added 25.9%	46,001 $660,000
Q4 2021 Feb 11, 2022	BUY	$15.44 - $27.32 $78,188 - $138,348	5,064 Added 16.09%	36,537 $721,000
Q3 2021 Nov 12, 2021	BUY	$20.7 - $34.69 $651,491 - $1.09 Million	31,473 New	31,473 $681,000

160

37.2M

70.4K

101K

Ticker JANX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,663,000
Market Cap $2.27B
Description
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.